Oculis Holding (OCS) Gets a Buy from Chardan Capital
Oculi Named as a 4th Batch of IC Taiwan Grand Challenge Winners
Oculis Advances Targeted Dry Eye Drug Licaminlimab Into Late-Stage Testing
Why Oculis Holding (OCS) Is Up 5.5% After Phase 3 DME Trial Milestone – And What's Next
Oculis Holding (OCS) Is Up 7.9% After EMA PRIME Tag For Optic Neuritis Drug Candidate
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis | OCS Stock News